# A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

> **NCT03751488** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Schizo Affective Disorder
- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** LY03010
- **DRUG:** Invega Sustenna 156 MG in 1 ML Prefilled Syringe

## Key facts

- **NCT ID:** NCT03751488
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2019-07-24
- **Final completion:** 2019-07-24
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751488, "A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03751488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*